File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation

TitleA validated pediatric disease risk index for allogeneic hematopoietic cell transplantation
Authors
Keywordschild
cytogenetics
hematopoietic stem cell transplantation
leukemia
pediatric disorders
Issue Date2021
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
Blood, 2021, v. 137 n. 7, p. 983-993 How to Cite?
AbstractA disease risk index (DRI) that was developed for adults with hematologic malignancy who were undergoing hematopoietic cell transplantation is also being used to stratify children and adolescents by disease risk. Therefore, to develop and validate a DRI that can be used to stratify those with AML and ALL by their disease risk, we analyzed 2569 patients aged <18 years with acute myeloid (AML; n = 1224) or lymphoblastic (ALL; n = 1345) leukemia who underwent hematopoietic cell transplantation. Training and validation subsets for each disease were generated randomly with 1:1 assignment to the subsets, and separate prognostic models were derived for each disease. For AML, 4 risk groups were identified based on age, cytogenetic risk, and disease status, including minimal residual disease status at transplantation. The 5-year leukemia-free survival for low (0 points), intermediate (2, 3, 5), high (7, 8), and very high (>8) risk groups was 78%, 53%, 40%, and 25%, respectively (P < .0001). For ALL, 3 risk groups were identified based on age and disease status, including minimal residual disease status at transplantation. The 5-year leukemia-free survival for low (0 points), intermediate (2-4), and high (≥5) risk groups was 68%, 51%, and 33%, respectively (P < .0001). We confirmed that the risk groups could be applied to overall survival, with 5-year survival ranging from 80% to 33% and 73% to 42% for AML and ALL, respectively (P < .0001). This validated pediatric DRI, which includes age and residual disease status, can be used to facilitate prognostication and stratification of children with AML and ALL for allogeneic transplantation.
Persistent Identifierhttp://hdl.handle.net/10722/305416
ISSN
2023 Impact Factor: 21.0
2023 SCImago Journal Rankings: 5.272
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorQayed, M-
dc.contributor.authorAhn, KW-
dc.contributor.authorKitko, CL-
dc.contributor.authorJohnson, MH-
dc.contributor.authorShah, NN-
dc.contributor.authorDvorak, C-
dc.contributor.authorMellgren, K-
dc.contributor.authorFriend, BD-
dc.contributor.authorVerneris, MR-
dc.contributor.authorLeung, W-
dc.contributor.authorToporski, J-
dc.contributor.authorLevine, J-
dc.contributor.authorChewning, JH-
dc.contributor.authorWayne, A-
dc.contributor.authorKapoor, U-
dc.contributor.authorTriplett, B-
dc.contributor.authorSchultz, KR-
dc.contributor.authorYanik, GA-
dc.contributor.authorEapen, M-
dc.date.accessioned2021-10-20T10:09:05Z-
dc.date.available2021-10-20T10:09:05Z-
dc.date.issued2021-
dc.identifier.citationBlood, 2021, v. 137 n. 7, p. 983-993-
dc.identifier.issn0006-4971-
dc.identifier.urihttp://hdl.handle.net/10722/305416-
dc.description.abstractA disease risk index (DRI) that was developed for adults with hematologic malignancy who were undergoing hematopoietic cell transplantation is also being used to stratify children and adolescents by disease risk. Therefore, to develop and validate a DRI that can be used to stratify those with AML and ALL by their disease risk, we analyzed 2569 patients aged <18 years with acute myeloid (AML; n = 1224) or lymphoblastic (ALL; n = 1345) leukemia who underwent hematopoietic cell transplantation. Training and validation subsets for each disease were generated randomly with 1:1 assignment to the subsets, and separate prognostic models were derived for each disease. For AML, 4 risk groups were identified based on age, cytogenetic risk, and disease status, including minimal residual disease status at transplantation. The 5-year leukemia-free survival for low (0 points), intermediate (2, 3, 5), high (7, 8), and very high (>8) risk groups was 78%, 53%, 40%, and 25%, respectively (P < .0001). For ALL, 3 risk groups were identified based on age and disease status, including minimal residual disease status at transplantation. The 5-year leukemia-free survival for low (0 points), intermediate (2-4), and high (≥5) risk groups was 68%, 51%, and 33%, respectively (P < .0001). We confirmed that the risk groups could be applied to overall survival, with 5-year survival ranging from 80% to 33% and 73% to 42% for AML and ALL, respectively (P < .0001). This validated pediatric DRI, which includes age and residual disease status, can be used to facilitate prognostication and stratification of children with AML and ALL for allogeneic transplantation.-
dc.languageeng-
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/-
dc.relation.ispartofBlood-
dc.rightsThis research was originally published in [Journal Title]. Author(s). Title. [Journal Title]. Year;Vol,Issue:pp-pp. © the American Society of Hematology.-
dc.subjectchild-
dc.subjectcytogenetics-
dc.subjecthematopoietic stem cell transplantation-
dc.subjectleukemia-
dc.subjectpediatric disorders-
dc.titleA validated pediatric disease risk index for allogeneic hematopoietic cell transplantation-
dc.typeArticle-
dc.identifier.emailLeung, W: leungwhf@hku.hk-
dc.identifier.authorityLeung, W=rp02760-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1182/blood.2020009342-
dc.identifier.pmid33206937-
dc.identifier.pmcidPMC7918183-
dc.identifier.scopuseid_2-s2.0-85101021587-
dc.identifier.hkuros327947-
dc.identifier.volume137-
dc.identifier.issue7-
dc.identifier.spage983-
dc.identifier.epage993-
dc.identifier.isiWOS:000646082000021-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats